Skip to content
OpenCapital
Get started

CorMedix CRMD Free cash flow yield

Free cash flow yield at other companies

Pfizer logo
PfizerPFE
7.8%+4.6pp
Merck & Co. logo
Merck & Co.MRK
4.7%-2.8pp
Merit Medical Systems logo
Merit Medical SystemsMMSI
5.4%+2.5pp
ITG
Integer HoldingsITGR
3.3%+0.6pp
IAR
Integra LifeSciencesIART
2.6%-2.1pp
Emergent Biosolutions logo
Emergent BiosolutionsEBS
32.9%—

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×—
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%—
Net margin45.2%—
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%—
Debt / equity0×0.0×
Current ratio3×-1.2×

Where this comes from

Calculated from CorMedix’s reported figures.

free cash flow/market cap=36.3%

Based on trailing twelve months.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's free cash flow yield?
CorMedix (CRMD) reported free cash flow yield of 36.3% in Q1 2026.
How has CorMedix's free cash flow yield changed year-over-year?
CorMedix's free cash flow yield increased by 1168.4% year-over-year, from -3.4% to 36.3%.
What is the long-term trend for CorMedix's free cash flow yield?
Over 5 years (2020 to 2025), CorMedix's free cash flow yield has grown at a 19.3% compound annual growth rate (CAGR), from -7.8% to 18.9%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.